Alliancebernstein L.P. Revance Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 3,260,471 shares of RVNC stock, worth $8.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,260,471

Previous 120,720 2600.85%

Holding current value

$8.38 Million

Previous $310,000 2602.9%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $8.07 Million - $8.07 Million	3,139,751 Added 2600.85%	3,260,471 $8.38 Million
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $70,714 - $142,940	30,220 Added 33.39%	120,720 $310,000
Q1 2024 May 14, 2024	SELL	$4.65 - $9.31 $2,325 - $4,655	-500 Reduced 0.55%	90,500 $445,000
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $28.7 Million - $62.8 Million	-2,505,263 Reduced 96.49%	91,000 $1.04 Million
Q2 2023 Aug 15, 2023	BUY	$24.7 - $37.61 $15.3 Million - $23.2 Million	617,706 Added 31.22%	2,596,263 $65.7 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $34.8 Million - $66.8 Million	1,894,157 Added 2244.26%	1,978,557 $63.7 Million
Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $587,101 - $982,561	-32,047 Reduced 27.52%	84,400 $1.56 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $316,800 - $561,000	-27,500 Reduced 19.1%	116,447 $1.61 Million
Q1 2022 May 13, 2022	BUY	$12.36 - $20.31 $2,472 - $4,061	200 Added 0.14%	143,947 $2.81 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $39.1 Million - $87.5 Million	-3,137,848 Reduced 95.62%	143,747 $2.35 Million
Q3 2021 Nov 10, 2021	BUY	$25.78 - $33.21 $5 Million - $6.44 Million	193,929 Added 6.28%	3,281,595 $91.4 Million
Q2 2021 Jul 30, 2021	SELL	$26.8 - $31.84 $7.12 Million - $8.46 Million	-265,613 Reduced 7.92%	3,087,666 $91.5 Million
Q1 2021 May 06, 2021	BUY	$24.03 - $29.97 $6.91 Million - $8.61 Million	287,375 Added 9.37%	3,353,279 $93.7 Million
Q4 2020 Feb 08, 2021	BUY	$23.41 - $28.34 $10.8 Million - $13.1 Million	462,388 Added 17.76%	3,065,904 $86.9 Million
Q3 2020 Nov 12, 2020	SELL	$23.23 - $34.3 $4.4 Million - $6.49 Million	-189,294 Reduced 6.78%	2,603,516 $65.5 Million
Q2 2020 Aug 13, 2020	BUY	$12.6 - $26.55 $7.32 Million - $15.4 Million	580,637 Added 26.25%	2,792,810 $68.2 Million
Q1 2020 May 14, 2020	BUY	$12.46 - $27.81 $3.25 Million - $7.26 Million	261,198 Added 13.39%	2,212,173 $32.7 Million
Q4 2019 Feb 18, 2020	SELL	$11.66 - $20.15 $1.43 Million - $2.46 Million	-122,236 Reduced 5.9%	1,950,975 $31.7 Million
Q3 2019 Nov 14, 2019	BUY	$10.22 - $14.5 $300,580 - $426,459	29,411 Added 1.44%	2,073,211 $27 Million
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $28,499 - $41,373	2,671 Added 0.13%	2,043,800 $26.5 Million
Q1 2019 May 14, 2019	BUY	$15.4 - $20.39 $7.39 Million - $9.79 Million	479,937 Added 30.74%	2,041,129 $32.2 Million
Q4 2018 Feb 13, 2019	SELL	$18.06 - $24.96 $1.64 Million - $2.27 Million	-90,757 Reduced 5.49%	1,561,192 $31.4 Million
Q3 2018 Nov 08, 2018	BUY	$23.55 - $30.1 $8.05 Million - $10.3 Million	341,896 Added 26.1%	1,651,949 $41.1 Million
Q2 2018 Aug 13, 2018	BUY	$27.45 - $33.35 $4.69 Million - $5.7 Million	170,942 Added 15.01%	1,310,053 $36 Million
Q1 2018 May 14, 2018	BUY	$29.15 - $37.4 $6.75 Million - $8.65 Million	231,416 Added 25.49%	1,139,111 $35.1 Million
Q4 2017 Feb 13, 2018	BUY	$24.55 - $36.3 $21.7 Million - $32.2 Million	885,895 Added 4063.74%	907,695 $32.5 Million
Q3 2017 Nov 13, 2017	BUY	$22.55 - $28.1 $491,590 - $612,580	21,800	21,800 $601,000

Others Institutions Holding RVNC

# of Institutions

230

Shares Held

81.5M

Call Options Held

617K

Put Options Held

870K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Revance Therapeutics, Inc. Transaction History